Skip to main content

Table 2 Comparison of progression between patients with solitary and multiple PTC

From: BRAFV600E status and clinical characteristics in solitary and multiple papillary thyroid carcinoma: experience of 512 cases at a clinical center in China

  Multiple PTC solitary PTC P value
Number 136 376  
Male/female 32/104 95/281 0.451
Mean age (yr) ± SD 44.3 ± 15.1 42.5 ± 17.4 0.226
Mean size (cm) ± SD 1.29 ± 1.44 1.67 ± 1.15 0.048
Micro variant 84 (61.8%) 147(39.1%) < 0.001
Tall cell variant 17 (12.5%) 38 (10.1%) 0.267
Extrathyroidal invasion 35 (25.9%) 93 (24.7%) 0.450
Vascular invasion 15 (11.0%) 16 (4.3%) 0.006
Hashimoto’s thyroiditis 36 (26.5%) 61 (16.2%) 0.007
Lymph node metastasis 74 (54.4%) 123 (32.7%) < 0.001
Distant metastasis 6 (4.4%) 14 (3.7%) 0.447
Recurrence 21 (15.4%) 15 (4.0%) < 0.001
10-year survival rate 125 (91.9%) 341 (90.7%) 0.579
BRAFv600E mutation 75 (55.1%) 188 (50%) 0.176
Family history 7 (5.1%) 6 (1.6%) 0.032
TNM stage    
  I 56 (41.2%) 186 (49.5%)  
  II 40 (29.4%) 111 (29.5%) 0.031
  III 24 (17.6%) 59 (15.7%)  
  IV 16 (11.8%) 20 (5.3%)  
  1. The TNM stage is based on the AJCC Cancer Staging Manual, 7th edition (2002).